INCB 54329

Drug Profile

INCB 54329

Alternative Names: INCB 054329; INCB54329

Latest Information Update: 12 May 2016

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class
  • Mechanism of Action BRD2-protein-inhibitors; BRD3 protein inhibitors; BRD4-protein-inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies; Solid tumours

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 14 Apr 2016 Data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 14 Apr 2016 Pharmacodynamics data from preclinical studies in Lymphoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top